Merck reported a positive result for its anti-TL1A antibody tulisokibart in the ATLAS-UC induction-only Phase 3 study in moderately to severely active ulcerative colitis. The company said the therapy met the primary endpoint of clinical remission at week 12 versus placebo on the Modified Mayo Score, with no safety concerns identified. Merck did not provide full dataset specifics in its initial release, but it said it will present detailed results at an upcoming scientific congress and share with regulators. The readout is the first reported 12-week clinical remission success for an anti-TL1A antibody in this patient population. Tulisokibart’s results also set up further differentiation questions across its ongoing induction and maintenance programs, as the UC field remains dominated by established IL-23 and JAK classes and defended by ongoing competitive trial data.